Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
A randomized phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Brian Slomovitz
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
A randomized Phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Trine Jakobi Nøttrup
Poster
T-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01)
Antonio González-Martín
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01, ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
Antonio J. González-Martín
Poster
T-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DE-02; GOG-3122/ENGOT-en30)
Cara Mathews
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DE-02; GOG-3122/ENGOT-en30)
Cara Mathews
Poster
R-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
Biomarker analysis of cadherin 6 (CHD6) and folate receptor alpha (FRα) expression, and raludotatug deruxtecan (R-DXd) antitumor activity by FRα status, in patients with platinum-resistant ovarian cancer from REJOICE-Ovarian01 and a first-in-human phase 1 study of R-DXd
Kathleen Moore
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Gynecologic Cancers
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
Poster
R-DXd
SGO 2026 | April 10-13, 2026
Gynecologic Cancers
Evaluating treatment patterns and outcomes of patients with platinum resistant ovarian cancer: Results of a real-world cohort in the United States
Ritu Salani
Poster
R-DXd
AACR 2026 | April 17-22, 2026
Gynecologic Cancers
Pharmacokinetic–tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer
YoungJun Yoo
